Fourth International Conference
ADJUVANT THERAPY OF PRIMARY BREAST CANCER

St. Gallen/Switzerland
February 26-29, 1992

Venue: OLMA-Messen, Kongresshalle 2

Topics: International Consensus Conference with Re-view of all Aspects of Adjuvant Chemo- Endocrine and Radiotherapy as well as Surgical Techniques and Psycho-Social Problems in Major Studies Worldwide

Language: English only

Exhibition: Scientific Posters, Industrial Exhibition

Abstract Deadline: October 31, 1991

Information: Mrs. Beatric Nair
Congress Secretariat
c/o Prof. H.J. Senn, Oncology Centre
Dept. Med. C, Kantonsspital
CH-9007 St. Gallen/Switzerland
Tel: (0) 71 26 10 97
Fax: (0) 71 25 68 05

---

R. Robert and Sally D. Funderburg
Research Scholar Awards in Gastric Cancer Biology

Starter grants will be offered to investigators to work in the fields of gastric mucosal cell regeneration and regulation of cell growth (not as they relate to peptic ulcer disease or repair), genetics, oncogenes, epidemiology, or etiology of gastric carcinoma; clinical research in the diagnosis or treatment of gastric carcinoma.

Candidates must hold faculty positions at accredited institutions. The funds are to be used for the salary of the investigator with an initial award of $25,000 per year for 2 years (no indirect costs). The application deadline for the first award will be October 1, 1991 with the first award to begin January 1992.

Applications and additional information can be obtained from SLACK, Inc., 6900 Grove Road, Thorofare, NJ 08086-9447.

Questions regarding the Program may be directed to George Y. Wu, M.D., Ph.D., University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030.

---

CHIEF - HEMATOLOGY/ONCOLOGY

The Lankenau Hospital, a 475 bed tertiary care institution affiliated with Thomas Jefferson Medical College, is seeking a Chief for the Division of Hematology-Oncology to enhance our existing program and provide intellectual, clinical and administrative leadership. Candidates must be board certified and have a distinct area of expertise in oncology. A Cancer Treatment Center is located on the premises with state of the art equipment.

The Lankenau Medical Research Center has been involved in basic and clinical research for over sixty years including many cancer projects.

Submit CV to:

Brendan Teahan, M.D.
President
Medical Staff
Lankenau Hospital
100 Lancaster Avenue
Wynnewood, PA 19096

---

ASSISTANT/ASSOCIATE OR FULL PROFESSOR
NEW DRUG DEVELOPMENT
The Ohio State University
Division of Hematology and Oncology

The Ohio State University seeks an M.D. or M.D./Ph.D. for an Assistant/Associate or Full Professor of Internal Medicine in the Division of Hematology and Oncology. Candidates should be board certified in Internal Medicine and board eligible in either hematology or oncology. Experience is required in clinical and laboratory research with a special interest in new drug development in which a leadership role is expected. This is a tenure-track, full-time position.

Please forward by June 30, 1991 a letter of application, curriculum vitae, bibliography, summary of research interests, and names and addresses of three references to:

Stanley P. Balcerzak, M.D.
The Ohio State University Hospitals
N-1021 Doan Hall
410 West Tenth Avenue
Columbus, OH 43210-1228

Ohio State University
Equal Opportunity/Affirmative Action Employer
The best weapon against breast cancer is early detection.
And that's why a mammogram is so important.
It "sees" breast cancer before there's a lump, when the cure rates are near 100%. That could save your life; it might even save your breast.
Although not perfect, a mammogram is still the most effective weapon against breast cancer.
And if you're over 35, it's essential you have one.
Because all breast cancer needs is a place to hide.

Have A Mammogram.
Give Yourself The Chance
Of A Lifetime.
This issue's cover features I. Bernard Weinstein, President of the American Association for Cancer Research (1990–1991). Dr. Weinstein received B.S. and M.D. degrees from the University of Wisconsin in 1952 and 1955, respectively. He interned at Montefiore Hospital, New York, from 1955 to 1957. He then became Clinical Associate at the National Cancer Institute from 1957 to 1959; Research Fellow in the Department of Bacteriology and Immunology at Harvard Medical School from 1959 to 1960; and Research Associate, Department of Biology at the Massachusetts Institute of Technology from 1960 to 1961. He was appointed Assistant Professor, then Associate Professor, at Columbia University College of Physicians and Surgeons and rose to the rank of Professor of Medicine in 1973. At present, he holds additional responsibilities as Attending Physician, Presbyterian Hospital, New York; Director of the Comprehensive Cancer Center and Frode Jensen Professor of Medicine; Director, Division of Oncology, Department of Medicine; and Professor of Genetics and Development and Public Health, all at Columbia University. During Dr. Weinstein's brilliant career, he has served on numerous advisory boards, committees, Editorial Boards, and study sections and has held offices in many professional societies, including the AACR, which elected him president in 1990. One of the highlights of his presidency is the launch of the Association's newest journal, Cancer Epidemiology, Biomarkers and Prevention, which will begin publication in November 1991. This publication, which emphasizes disciplines in which Dr. Weinstein has substantial expertise, will focus on important scientific achievements in cancer prevention. Because of his intense interest and concern for increased funding for cancer research, he has fostered progress in the AACR's public education program. Further, he has expanded the Association's role in international scientific activities.

In his early research, Weinstein was one of the first to obtain evidence that the genetic code is universal and that the code of neoplastic cells is the same as that of normal cells. Since 1970, his group has been one of the world's leading laboratories in the field of chemical carcinogenesis. His fundamental studies on carcinogen-DNA adducts led to the development of highly sensitive immunoassays for the detection of carcinogen-DNA adducts, which Dr. Weinstein has used, along with related approaches, to develop the concept of molecular epidemiology.

He has also made major advances in understanding the mechanisms of action of tumor promoters and has demonstrated synergistic interactions among tumor promoters, viruses, and activated oncogenes in the process of cell transformation. He was the first to report the isolation and sequence analysis of complementary DNAs related to protein kinase C and to provide evidence that this enzyme belongs to a multigene family. In very recent studies he has provided direct evidence that protein kinase C plays a critical role in growth control, tumor promotion, oncogene action, and the origin of specific human cancers. He has also developed inhibitors of protein kinase C, which may prove useful in cancer prevention and therapy.

In recognition of his fundamental contributions to cancer research, Dr. Weinstein received the Clowes Award of the American Association for Cancer Research in 1987. He recently received the 1990 Silvio D. Conte Award of the Environmental Health Institute for his pivotal studies on environmental carcinogenesis and molecular cancer epidemiology.